^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Dawn™

Type:
Laboratory Developed Test
Related tests:
Evidence

News

almost2years
InterVenn Biosciences announces new data validating the clinical performance of DAWN™ IO Melanoma as a novel liquid biopsy test to improve assessment of benefit to cancer patients (Businesswire)
"InterVenn® Biosciences...announced new data showing that its new DAWN IO Melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies: either pembrolizumab alone or ipilimumab in combination with nivolumab."
Retrospective data
|
Dawn™